LCB84 is a TROP2-targeted ADC. It binds TROP2, is internalized, and releases MMAE, which binds beta-tubulin (vinca site) to disrupt microtubules, causing G2/M arrest and apoptosis. Killing depends on TROP2-mediated delivery (with possible bystander effect), not on beta-tubulin expression alone.